CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
University of Rochester
M.D. Anderson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Northside Hospital, Inc.
West Virginia University
National Institutes of Health Clinical Center (CC)
The University of Queensland
National Institutes of Health Clinical Center (CC)
Quetzal Therapeutics
Technical University of Munich
National Institutes of Health Clinical Center (CC)
Kousai Bio Co., Ltd.
Universität Duisburg-Essen
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Immunome, Inc.
Orca Biosystems, Inc.
M.D. Anderson Cancer Center
Kura Oncology, Inc.
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Center for International Blood and Marrow Transplant Research
National Cancer Institute (NCI)
University of Wisconsin, Madison
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
Merck Sharp & Dohme LLC
Alliance for Clinical Trials in Oncology
Ohio State University Comprehensive Cancer Center
University of Florida
University of Alabama at Birmingham
National Cancer Institute (NCI)